Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma”

Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma”

Saved in:

Bibliographic Details
Main Authors:	Tingting Zhang, Tianyuan Ren, Zheng Song, Jing Zhao, Lei Jiao, Zhenzhen Zhang, Jin He, Xianming Liu, Lihua Qiu, Lanfang Li, Shiyong Zhou, Bin Meng, Qiongli Zhai, Xiubao Ren, Zhengzi Qian, Xianhuo Wang, Huilai Zhang
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2021/4972043
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Differential impact of TIM-3 ligands on NK cell function
by: Xin Zhang, et al.
Published: (2025-01-01)

TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection.
by: Pushpa Jayaraman, et al.
Published: (2016-03-01)

Commentary on differential impact of TIM-3 ligands on NK cell function
by: Rieneke van de Ven
Published: (2025-07-01)

TIM‐3 as a potential exhaustion marker in CD4+ T cells of COVID‐19 patients
by: Zahra Modabber, et al.
Published: (2021-12-01)

TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8+T cell exhaustion
by: Xuhao Zhang, et al.
Published: (2025-06-01)

Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection.
by: Gaia Nebbia, et al.
Published: (2012-01-01)

TIM-3 expression on monocyte-derived dendritic cells
by: T. V. Tyrinova, et al.
Published: (2024-09-01)

The Role of TIM-3 in Glioblastoma Progression
by: Farah Ahmady, et al.
Published: (2025-02-01)

The effect of TIM1+ Breg cells in liver ischemia-reperfusion injury
by: Yu Zhang, et al.
Published: (2025-03-01)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
by: Tingting Zhang, et al.
Published: (2022-04-01)

Advances in the study of TIM3 in myelodysplastic syndrome
by: Xinyu Guo, et al.
Published: (2025-08-01)

Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation
by: Farah Ahmady, et al.
Published: (2024-10-01)

Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression
by: Jialiu Luo, et al.
Published: (2024-12-01)

Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma
by: Wenhui Ge, et al.
Published: (2017-06-01)

Characterization and prognostic of CD8 + TIM3 + CD101 + T cells in glioblastoma multiforme
by: Hong-Liang Wang, et al.
Published: (2025-05-01)

Analysis of Tim-3 as a therapeutic target in prostate cancer
by: Yongrui Piao, et al.
Published: (2017-07-01)

Galectin-9 and Tim-3 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti-PD-1 blockade
by: Charlotte N. Hill, et al.
Published: (2025-07-01)

Activated Tim-3/Galectin-9 participated in the development of multiple myeloma by negatively regulating CD4 T cells
by: Rui Zhang, et al.
Published: (2024-12-01)

Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
by: Chenyu Lu, et al.
Published: (2024-03-01)

Tim Burton — L’exposition
by: Clémence Simon
Published: (2012-10-01)

Tim Dowley, Bibelatlas kompakt
by: S. J. P. K. Riekert
Published: (2006-12-01)

Tim-3 Is Differentially Expressed during Cell Activation and Interacts with the LSP-1 Protein in Human Macrophages
by: Ranferi Ocaña-Guzman, et al.
Published: (2023-01-01)

Expression of inhibitory receptors PD-1, CTLA-4, and Tim-3 by peripheral T cells during pregnancy
by: E. A. Smetanenko, et al.
Published: (2022-10-01)

TIM3 and TIGIT-expressing CD4 T cells are impacted by kidney transplantation and associated with risk of infection
by: Harry Pickering, et al.
Published: (2025-05-01)

Unraveling the immunomodulatory role of TIM-3 in head and neck squamous cell carcinoma: implications for targeted therapy
by: Shuang Xu, et al.
Published: (2025-05-01)

Tim-3 is dispensable for allergic inflammation and respiratory tolerance in experimental asthma.
by: Carolin Boehne, et al.
Published: (2021-01-01)

LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy
by: Camil Ciprian Mireștean, et al.
Published: (2025-04-01)

Lessons from the Tim Greenamyre model
by: Laurie H. Sanders, et al.
Published: (2025-09-01)

Response to letter from Tim Bailey
by: J.M. Wilkinson, et al.
Published: (2020-11-01)

PENGARUH INSTRUMENTAL DAN EXPRESSIVE NETWORK DENSITY TERHADAP KINERJA TIM: PEMEDIASI KEMAMPUAN INTEGRASI PENGETAHUAN TIM
by: Candra Vionela Merdiana, et al.
Published: (2016-01-01)

Calcidius on the Conformity of the Platonist Doctrine and Jewish Philosophy (in Tim. 256: 3-11)
by: Maya S. PETROVA
Published: (2025-04-01)

TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
by: Zhuohong Yan, et al.
Published: (2025-05-01)

Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma
by: Ivan Pourmir, et al.
Published: (2025-02-01)

Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients
by: Qi Xia, et al.
Published: (2018-01-01)

Blocking Tim-3 enhances CD8+ T cell activity to inhibit hepatocellular carcinoma recurrence post-radiofrequency ablation
by: Na Wu, et al.
Published: (2025-12-01)

The Functional Role and Prognostic Significance of TIM-3 Expression on NK Cells in the Diagnostic Bone Marrows in Acute Myeloid Leukemia
by: Kai Sun, et al.
Published: (2024-11-01)

TIM-3-driven macrophage polarisation is associated to recalcitrant chronic rhinosinusitis with nasal polyps
by: Tao Jiang, et al.
Published: (2024-08-01)

CD56 and Tim-3 molecule expression in different monocyte subsets in physiological pregnancy
by: E. G. Orlova, et al.
Published: (2023-06-01)

Effect of the TIM-3/Gal-9 signaling pathway on macrophage polarization in peri-implantitis.
by: Lu-Jin Cheng, et al.
Published: (2025-01-01)

Tim O'Brien: Theme Park Perspective
by: Tim O'Brien
Published: (2021-03-01)